Tuberc Respir Dis > Accepted Articles
DOI:    [Accepted]
Published online March 28, 2024.
Contemporary Strategies: Incorporating Immunotherapy into Stage III Non-Small Cell Lung Cancer Treatment
Da Hyun Kang, Chaeuk Chung
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, 266, Munhwa-ro, Jung-gu, Daejeon, 35015, Republic of Korea
Correspondence:  Chaeuk Chung,
Received: 8 October 2023   • Revised: 22 January 2024   • Accepted: 22 March 2024
Stage III non-small cell lung cancer (NSCLC) exhibits significant diversity, making it challenging to define an optimal treatment. A collaborative multidisciplinary approach is essential in crafting individualized treatments. Previously, targeted therapies and immunotherapies were commonly used to treat patients with advanced and metastatic lung cancer. Such treatments are now being extended to individuals considered surgery, as well as patients once considered unsuitable for surgery. These changes have increased surgical success and substantially reduced postoperative recurrence. However, the possibility of severe adverse effects from immunotherapy can deter some patients from performing surgery. It is essential to carefully explore the clinical traits and biomarkers of patients who may benefit the most from immunotherapy, and patients for whom immunotherapy should not be prescribed. In summary, it's crucial to effectively integrate the latest immunotherapy in treating stage III NSCLC patients, thereby increasing their opportunities for surgical intervention, and ensuring they receive the best possible care.
Key Words: Immunotherapy, Non-small cell lung cancer, Consolidation, Surgery, Adjuvant treatment, Neoadjuvant treatment

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next